2024/12/31 by Ugo Testa, Giuseppe Leone · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Treatment and Pharmacology #Multiple Myeloma Research and Treatments #Protein Degradation and Inhibitors
paper · pdf · doi:10.4084/mjhid.2025.005
openalex publication_date 2024/12/31 · openalex created_date 2025/01/02 · openalex updated_date 2026/07/15
Multiple myeloma is a disease related to the proliferation of malignant plasma cells; in most patients, the disease is confined to the level of bone marrow. However, in a minority of patients, the malignant plasma cells are also localized outside the bone marrow, either at the level of peripheral blood (plasma cell leukemia) or at the level of soft tissues (extramedullary multiple myeloma). These two rare forms of aggressive MM (ultrahigh-risk (uHR) MM as MM leading to death within 24-36 months) are both associated with some molecular features and with a limited response to current treatments.